Vitro Biopharma (VTRO) 10-Q 16 Sep 24 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Jul. 31, 2024	Sep. 16, 2024
Entity Addresses [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jul. 31, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--10-31
Entity File Number	001-41766
Entity Registrant Name	VITRO BIOPHARMA, INC.
Entity Central Index Key	0000793171
Entity Tax Identification Number	84-1012042
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3200 Cherry Creek Drive South
Entity Address, Address Line Two	Suite 410
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80209
City Area Code	(855)
Local Phone Number	848-7627
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,460,535
Entity Listing, Par Value Per Share	$ 0.001
Former Address [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	3200 Cherry Creek Drive South
Entity Address, Address Line Two	Suite 410
Entity Address, City or Town	Denver
Entity Address, State or Province	CO

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jul. 31, 2024	Oct. 31, 2023
ASSETS
Cash	$ 1,543,088	$ 101,754
Accounts Receivable, Net	69,067	119,671
Inventory	214,568	170,752
Prepaid Expense	105,190	130,851
Deferred Offering Costs		2,656,326
Total Current Assets	1,931,913	3,179,354
Goodwill	3,608,949	3,608,949
Intangible Assets, Net	616,965	667,813
Property and Equipment, Net	180,316	320,414
Patents, Net	82,959	82,325
Right of Use Asset – Operating Lease	377,797	476,241
Other Assets	8,438	8,438
Total Assets	6,807,337	8,343,534
LIABILITIES
Accounts Payable	2,318,618	2,288,697
Deferred Revenue, Net	525,387	525,387
Accrued Liabilities	1,599,391	1,310,240
2021 Series Convertible Note Payable – Related Party	480,000	480,000
Accrued Interest Payable – Related Party	72,000	53,804
2024 Series Senior Secured Convertible Notes Payable – Stock Settled, Net	4,864,783
Derivative/Warrant Liability	155,458
Current Maturities of Capital Lease Obligations	21,052	61,832
Current Maturities of Operating Lease Obligations	122,140	130,150
Total Current Liabilities	10,158,829	4,850,110
Capital Lease Obligations, Net of Current Portion	7,704	17,123
Operating Lease Obligation, Net of Current Portion	255,657	346,091
Unsecured 6% Note Payable – Related Party	767,288	767,288
Unsecured 4% Note Payable – Related Party	1,221,958	1,221,958
2022 Series Convertible Notes Payable	200,000	200,000
2023 Series Convertible Notes Payable - Stock Settled, Net	349,847	340,715
2023 Series B Convertible Notes Payable – Stock Settled, Net	482,204	421,018
Derivative/Warrant Liability	126,878	893,263
Long Term Accrued Interest Payable	202,968	92,311
Long Term Accrued Interest Payable – Related Party	355,999	284,747
Total Long-Term Liabilities	3,970,503	4,584,514
Total Liabilities	14,129,332	9,434,624
STOCKHOLDERS’ (DEFICIT)
Preferred Stock, 5,000,000 Shares Authorized, par value $0.001; Series A Convertible Preferred Stock, 250,000 Shares Authorized, 0 and 0 Outstanding, respectively
Common stock, 19,230,770 Shares Authorized, par value $0.001, 4,460,535 and 4,430,535 Outstanding, respectively	4,460	4,430
Additional Paid in Capital	28,670,863	27,064,613
Less Treasury Stock	(84,000)	(84,000)
Accumulated Deficit	(35,913,318)	(28,076,133)
Total Stockholders’ (Deficit)	(7,321,995)	(1,091,090)
Total Liabilities and Stockholders’ (Deficit)	$ 6,807,337	$ 8,343,534

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jul. 31, 2024	Oct. 31, 2023
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	19,230,770	19,230,770
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares outstanding	4,460,535	4,430,535
Series A Preferred Stock [Member]
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Total Revenue	$ 319,909	$ 577,240	$ 1,317,056	$ 1,229,114
Less Cost of Goods Sold	(65,438)	(96,815)	(244,802)	(225,960)
Gross Profit	254,471	480,425	1,072,254	1,003,154
Operating Costs and Expenses:
Selling, General and Administrative	1,383,346	1,486,866	5,068,793	4,445,217
Research and Development	125,628	33,146	421,552	106,426
Write-off of Offering Costs			2,656,962
Loss From Operations	(1,254,503)	(1,039,587)	(7,075,053)	(3,548,489)
Other Expense:
Interest Expense	(1,950,925)	(81,976)	(4,282,853)	(178,606)
Other Project Income, Net		191,746		191,746
Gain on Extinguishment of Debt	740,724		740,724
Unrealized Gain on Derivative/Warrant Liability	2,315,624	58,133	2,779,997	58,840
Net Loss Available to Common Stockholders	$ (149,080)	$ (871,684)	$ (7,837,185)	$ (3,476,509)
Net Loss per Common Share, Basic	$ (0.03)	$ (0.20)	$ (1.76)	$ (0.78)
Net Loss per Common Share, Diluted	$ (0.03)	$ (0.20)	$ (1.76)	$ (0.78)
Shares Used in Computing Net Loss per Common Share, Basic	4,460,535	4,430,535	4,458,783	4,430,535
Shares Used in Computing Net Loss per Common Share, Diluted	4,460,535	4,430,535	4,458,783	4,430,535
Product [Member]
Total Revenue	$ 318,109	$ 561,490	$ 1,299,056	$ 1,170,364
Product Sales Related Parties [Member]
Total Revenue	$ 1,800	$ 15,750	18,000	33,750
Consulting Revenue [Member]
Total Revenue				$ 25,000

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	Total
Balance at Oct. 31, 2022		$ 4,430	$ 25,634,826	$ (84,000)	$ (22,719,416)	$ 2,835,840
Balance, shares at Oct. 31, 2022		4,430,535
Forgiven Accrued Payables – Related Party			137,953			137,953
Stock Based Compensation			122,562			122,562
Net Loss					(1,190,125)	(1,190,125)
Balance at Jan. 31, 2023		$ 4,430	25,895,341	(84,000)	(23,909,541)	1,906,230
Balance, shares at Jan. 31, 2023		4,430,535
Balance at Oct. 31, 2022		$ 4,430	25,634,826	(84,000)	(22,719,416)	2,835,840
Balance, shares at Oct. 31, 2022		4,430,535
Net Loss						(3,476,509)
Balance at Jul. 31, 2023		$ 4,430	26,675,031	(84,000)	(26,195,925)	399,536
Balance, shares at Jul. 31, 2023		4,430,535
Balance at Oct. 31, 2022		$ 4,430	25,634,826	(84,000)	(22,719,416)	2,835,840
Balance, shares at Oct. 31, 2022		4,430,535
Net Loss						(5,400,000)
Balance at Oct. 31, 2023		$ 4,430	27,064,613	(84,000)	(28,076,133)	(1,091,090)
Balance, shares at Oct. 31, 2023		4,430,535
Balance at Jan. 31, 2023		$ 4,430	25,895,341	(84,000)	(23,909,541)	1,906,230
Balance, shares at Jan. 31, 2023		4,430,535
Stock Based Compensation			393,510			393,510
Net Loss					(1,414,700)	(1,414,700)
Balance at Apr. 30, 2023		$ 4,430	26,288,851	(84,000)	(25,324,241)	885,040
Balance, shares at Apr. 30, 2023		4,430,535
Stock Based Compensation			386,616			386,616
Net Loss					(871,684)	(871,684)
Payment for Fractional Warrants - Recapitalization			(436)			(436)
Balance at Jul. 31, 2023		$ 4,430	26,675,031	(84,000)	(26,195,925)	399,536
Balance, shares at Jul. 31, 2023		4,430,535
Balance at Oct. 31, 2023		$ 4,430	27,064,613	(84,000)	(28,076,133)	(1,091,090)
Balance, shares at Oct. 31, 2023		4,430,535
Stock Based Compensation			384,484			384,484
Net Loss					(4,569,186)	(4,569,186)
Stock Issued for Services		$ 30	449,970			450,000
Stock Issued for Services, shares		30,000
Balance at Jan. 31, 2024		$ 4,460	27,899,067	(84,000)	(32,645,319)	(4,825,792)
Balance, shares at Jan. 31, 2024		4,460,535
Balance at Oct. 31, 2023		$ 4,430	27,064,613	(84,000)	(28,076,133)	(1,091,090)
Balance, shares at Oct. 31, 2023		4,430,535
Net Loss						(7,837,185)
Balance at Jul. 31, 2024		$ 4,460	28,670,863	(84,000)	(35,913,318)	(7,321,995)
Balance, shares at Jul. 31, 2024		4,460,535
Balance at Jan. 31, 2024		$ 4,460	27,899,067	(84,000)	(32,645,319)	(4,825,792)
Balance, shares at Jan. 31, 2024		4,460,535
Stock Based Compensation			388,367			388,367
Net Loss					(3,118,919)	(3,118,919)
Balance at Apr. 30, 2024		$ 4,460	28,670,863	(84,000)	(35,764,238)	(7,556,344)
Balance, shares at Apr. 30, 2024		4,460,535
Stock Based Compensation			383,429			383,429
Net Loss					(149,080)	(149,080)
Balance at Jul. 31, 2024		$ 4,460	$ 28,670,863	$ (84,000)	$ (35,913,318)	$ (7,321,995)
Balance, shares at Jul. 31, 2024		4,460,535

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Jul. 31, 2024	Jan. 31, 2024	Jul. 31, 2023	Jan. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Oct. 31, 2023
Operating Activities
Net Loss	$ (149,080)	$ (4,569,186)	$ (871,684)	$ (1,190,125)	$ (7,837,185)	$ (3,476,509)	$ (5,400,000)
Adjustment to Reconcile Net Loss:
Other Project Income, Net			(191,746)			(191,746)
Gain on Extinguishment of Debt	(740,724)				(740,724)
Unrealized Gain on Derivative/Warrant Liability					(2,779,997)	(58,840)
Depreciation Expense	48,313		39,706		140,098	117,745
Amortization Expense					50,848	98,802
Amortization of Operating Lease – ROU Asset	32,103		12,345		98,444	38,032
Accretion of Debt Discount					4,069,895	21,143
Stock Based Compensation	383,429		386,616		1,156,280	902,688
Common Stock Issued for Services					450,000
Write-off of Offering Costs					2,656,962
Changes in Assets and Liabilities
Accounts Receivable					50,604	(5,765)
Inventory					(43,816)	92,309
Prepaid Expenses					25,661	29,455
Prepaid project costs						(125)
Accounts Payable					29,285	194,497
Accounts Payable – Related Party						11,289
Deferred Revenue						285,005
Operating Lease Obligation					(98,444)	(38,032)
Accrued Liabilities					289,151	(32,745)
Accrued Liabilities – Related Party						(94,995)
Accrued Interest					110,657	51,951
Accrued Interest – Related Parties					89,448	88,942
Net Cash Used in Operating Activities					(2,282,833)	(1,966,899)
Investing Activities
Acquisition of Property and Equipment						(127,158)
Patent Costs					(634)	(29,893)
Other Assets						(3,238)
Net Cash Used in Investing Activities					(634)	(160,289)
Financing Activities
Issuance of 2024 Series Senior Secured Convertible Notes Payable – Stock Settled					3,775,000
Issuance of 2023 Series Convertible Notes Payable - Stock Settled						405,000
Issuance of 2023 Series B Convertible Notes Payable – Stock Settled						1,312,600
Capital Lease Principal Payments					(50,199)	(46,775)
Net Cash Provided by Financing Activities					3,724,801	1,670,825
Total Cash Provided (Used) During the Period					1,441,334	(456,363)
Beginning Cash Balance		$ 101,754		$ 741,538	101,754	741,538	741,538
Ending Cash Balance	$ 1,543,088		$ 285,175		1,543,088	285,175	$ 101,754
Cash Paid for Interest					12,853	16,570
Cash Paid for Income Taxes
Supplemental Schedule of Non-Cash Financing Activities:
Premium on issuance of 2024 Series Senior Secured Notes Payable - Stock Settled					2,895,835
Derivative/Warrant Liability on 2024 Series Senior Secured Notes Payable					3,159,788
Discount on Derivative/Warrant Liability on 2024 Series Senior Secured Notes Payable					6,055,624
Premium on issuance of 2023 Series Notes Payable						572,533
Derivative/Warrant Liability on 2023 Series Notes Payable						996,597
Discount on Derivative/Warrant Liability on 2023 Series Notes Payable						1,569,130
Forgiveness of Accrued Liabilities – Related Party						137,953
Deferred Offering Costs Recorded as Accounts Payable						1,001,788
Right of Use Asset						$ 271,396

NATURE OF ORGANIZATION AND SUMM

NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Jul. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Organization and Description of Business Vitro Biopharma, Inc. (the “Company”) was incorporated under the laws of the State of Nevada on March 31, 1986, under the name Imperial Management, Inc. On December 17, 1986, the Company merged with Labtek, Inc., a Colorado corporation, with the Company being the surviving entity and the name of the Company was changed to Labtek, Inc. The name was then changed to Vitro Diagnostics, Inc. on February 6, 1987. From November of 1990 through July 31, 2000, the Company was engaged in the development, manufacturing, and distribution of purified human antigens (“Diagnostics”) and related technologies. The Company also developed cell technology including immortalization of certain cells, which allowed entry into other markets besides Diagnostics. In August 2000, the Company sold the Diagnostics business, following which it focused on developing therapeutic products, its stem cell technology, patent portfolio and proprietary technology and cell lines for applications in autoimmune disorders and inflammatory disease processes and stem cell research. On February 3, 2021, the Company filed an amendment to the articles of incorporation with the Nevada Secretary of State, changing the name of the Company to Vitro BioPharma, Inc. Summary of Significant Accounting Policies Basis of Presentation The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended October 31, 2023, as filed with the SEC (“Form 10-K”). Unless otherwise noted in this Interim Report, there have been no material changes to the disclosures contained in the notes to the audited financial statements for the year ended October 31, 2023, contained in the Form 10-K. The Consolidated Balance Sheet as of October 31, 2023, was derived from the audited financial statements included in the Form 10-K. In management’s opinion, the unaudited interim Consolidated Balance Sheet, Statements of Operations, Statements of Changes in Shareholders’ Equity, and Statements of Cash Flows, contained herein, reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company’s financial position, results of operations and cash flows on a basis consistent with that of the Company’s prior audited consolidated financial statements. The results of operations for the interim periods may not be indicative of results to be expected for the full fiscal year. Certain prior period amounts were reclassified to conform to the current presentation on the Consolidated Financial Statements. The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Basis of Consolidation The consolidated financial statements include the operations of the Company and its wholly owned subsidiaries, Fitore, Inc. (“Fitore”) and InfiniVive MD, LLC (“InfiniVive”). Cash Equivalents For the purposes of the Statements of Cash Flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage limits. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Concentrations During the nine months ended July 31, 2024 and 2023, 1 3 30 37 25 10 38 10 25,000 4 Deferred Offering Costs The Company defers, as Current Assets, the direct incremental costs of raising capital through equity offerings, until such time as the offering is completed or abandoned. At the time of the offering completion, the costs are charged against the capital raised. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated. During the nine months ended July 31, 2024 and 2023 the Company recorded as expense $ 2,656,962 0 Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets. Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue Recognition As of January 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on the Company’s consolidated financial statements. For each performance obligation identified in accordance with ASC 606, the Company determines at contract inception whether it satisfies the performance obligation over time (in accordance with paragraphs 606-10-25-27 through 25-29) or satisfies the performance obligation at a point in time (in accordance with paragraph 606-10-25-30). If an entity does not satisfy a performance obligation over time, the performance obligation is satisfied at a point in time. Control is considered transferred over time if any one of the following criteria is met: ● The customer simultaneously receives and consumes the benefits of the asset or service which the entity performs; ● The entity’s performance creates or enhances an asset; or ● The entity’s performance creates or enhances an asset that has no alternative use to the entity and the entity has the right to payment for work completed to date. For certain contracts to which the Company is party, it uses the recognition over time method to recognize revenue. The Company recognizes revenue when performance obligations with the customer are satisfied. Product sales occur once control is transferred upon shipment to the customer at the time of the sale. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods and services. The Company’s revenue is primarily derived from the sources listed below: Sale of research and development product Sales of research and development product include the sale of stem cell medium Sale of therapeutic product: Includes cell culture media to be used in therapeutic treatment. Shipping: Includes amounts charged to customers for shipping products. Consulting Revenue: The Company has agreed to assist another party to develop an FDA-approved biological product. Revenues are recognized when certain contractual milestones are achieved. Fitore product sales online: Includes internet sales, via the Fitore Nutrition website, of dietary supplements called Stemulife, Spectrum+, Easy Sleep and Thought Calmer. InfiniVive product sales: InfiniVive, via call-in orders, sells exosomes and daily cosmetic serum Disaggregation of revenue The following table summarizes the Company’s revenue for the reporting periods, disaggregated by product or service type: SCHEDULE OF DISAGGREGATION OF REVENUE Three Months Three Months Revenues: Research and development products $ 72,913 $ 284,306 AlloRx Stem Cells to Foreign Third-Party Clinics 214,839 217,991 InfiniVive products 29,236 60,160 Fitore products 2,921 14,783 Total $ 319,909 $ 577,240 Total Revenues $ 319,909 $ 577,240 Nine Months Nine Months Revenues: Research and development products $ 322,870 $ 307,324 AlloRx Stem Cells to Foreign Third-Party Clinics 870,712 661,208 Consulting revenue - 25,000 InfiniVive products 110,817 183,148 Fitore products 12,657 52,434 Total $ 1,317,056 $ 1,229,114 Total Revenues $ 1,317,056 $ 1,229,114 Deferred Revenue The Company has recorded deferred revenue in connection with a Joint Operating Agreement (as subsequently amended, the “JOA”) between the Company and European Wellness/BIO PEP USA (“BIO PEP”). Pursuant to this JOA, which expired in accordance with its terms on July 31, 2023 and has not been renewed, the Company was obligated to use its best efforts to identify, develop and deliver various potential active pharmaceutical ingredients and to oversee the development of a recombinant cell line by a third-party service provider. The Company was also engaged to establish a Quality Management System to be utilized by BIO PEP in their pursuit of FDA authorizations. Prior to its expiration, our work under the JOA had been suspended since April 2023 pending discussions regarding amounts believed to be owed to us under that agreement for work already completed. If those discussions are unsuccessful, we may not be able to collect all of the amounts believed to be owed to us or the other amounts originally expected to be received by us under the agreement. The Company records as deferred revenue amounts for which the Company has been paid but for which it has not yet achieved and delivered related milestones or when the level of effort required to complete performance obligations under an arrangement cannot be reasonably estimated under the terms of the related agreement. Deferred revenue is classified as current or long-term based on when management estimates the revenue will be recognized. As of July 31, 2024, the Company has net deferred $ 525,387 685,005 159,618 The table below summarizes Deferred Revenues as of July 31, 2024: SUMMARY OF DEFERRED REVENUES October 31, Other Project Net Revenue July 31, Deferred Revenue $ 525,387 $ - $ - $ 525,387 Total $ 525,387 $ - $ - $ 525,387 The table below summarizes Deferred Revenues as of July 31, 2023: October 31, Revenue Recognized Revenue July 31, Deferred Revenue $ 650,000 $ (250,000 ) $ 285,005 $ 685,005 Total $ 650,000 $ (250,000 ) $ 285,005 $ 685,005 As of July 31, 2023, upon the expiration of the European Wellness Agreement, the Company recognized $ 250,000 58,254 Accounts Receivable Accounts receivable consists of amounts due from customers. The Company considers accounts more than 30 days old to be past due. The Company uses the allowance method for recognizing bad debts. When an account is deemed uncollectible, it is written off against the allowance. The Company generally does not require collateral for its accounts receivable. As of July 31, 2024 and October 31, 2023, total accounts receivable amounted to $ 69,067 119,671 975 975 As of July 31, 2024, two customers accounted for 46 14 39 35 Basic Loss Per Share The Company complies with accounting and disclosure requirements ASC Topic 260, “Earnings Per Share.” Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic income or loss per share) and potentially dilutive shares of common stock that are not anti-dilutive. For the nine months ended July 31, 2024 and 2023, the following number of potentially dilutive shares have been excluded from diluted net loss since such inclusion would be anti-dilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE July 31, 2024 July 31, 2023 Stock options outstanding 1,112,923 1,122,154 Shares to be issued in connection with exercise of warrants 330,608 448,677 2021 Series Convertible Notes Payable - Related Party – common shares 18,462 18,462 2022 Series Convertible Notes Payable - common shares 7,692 7,692 2023 Series Convertible Notes Payable – Stock Settled 30,371 12,854 2023 Series Convertible Notes Payable – Stock Settled – warrants issuable 3,076 3,076 2023 Series B Convertible Notes Payable – Stock Settled 96,286 40,683 2023 Series B Convertible Notes Payable - Stock Settled - warrants issuable 39,881 39,881 2024 Series Senior Secured convertible notes payable – stock settled 398,768 - 2024 Series Senior Secured convertible notes payable – stock settled – warrants issuable- 289,583 - 2024 Pre-funded Warrants 1,060,000 - Total 3,387,650 1,693,479 Anti-dilutive shares 3,387,650 1,693,479 Inventory Inventories, consisting of raw materials and finished goods, are stated at the lower of cost (using the specific identification method) or market. Inventories consisted of the following at the balance sheet dates: SCHEDULE OF INVENTORIES July 31, 2024 October 31, 2023 Raw materials $ 21,182 $ 18,856 Finished goods 193,386 151,896 Total inventory $ 214,568 $ 170,752 The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. During the nine months ended July 31, 2024 and 2023, the Company did not record any impairment expense. Patents Costs related to filing and pursuing patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) are capitalized as incurred and will not be amortized until a patent is granted at which time they will be amortized. Capitalized patent costs recorded as of July 31, 2024 and October 31, 2023 were $ 82,959 82,325 Recent Accounting Standards On August 5, 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, “Debt – Debt With Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40),” which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in GAAP. This ASU is effective for fiscal years beginning after December 31, 2023. The Company is evaluating the impact the adoption will have on the financial statements.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Jul. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. The Company incurred net losses of approximately $ 7.8 5.4 8.2 These factors raise substantial doubt about the Company’s ability to continue as a going concern. In view of these matters, realization of certain of the assets in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and generate additional revenues and profit from operations. Management plans to address the going concern include but are not limited to raising additional capital through an attempted public and/or private offering of equity securities, as well as potentially issuing additional debt instruments. The Company also has various initiatives underway to increase revenue generation through diversified offerings of products and services related to its stem cell technology and analytical capabilities. The goal of these initiatives is to achieve profitable operations as quickly as possible. Various strategic alliances that are ongoing and under development are also critical aspects of management’s overall growth and development strategy. There is no assurance that these initiatives will yield sufficient capital to maintain the Company’s operations. There is no assurance that the ongoing capital raising efforts will be successful. Should management fail to successfully raise additional capital and/or fully implement its strategic initiatives, it may be compelled to curtail part or all of its ongoing operations. The financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has historically financed its operations primarily through various private placements of debt and equity securities.

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	9 Months Ended
	Jul. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	NOTE 3 – FAIR VALUE MEASUREMENT ASC Topic 820, “Fair Value Measurements and Disclosures”, establishes a hierarchy for inputs used in measuring fair value for financial assets and liabilities that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of the inputs as follows: ● Level 1: Quoted prices available in active markets for identical assets or liabilities; ● Level 2: Quoted prices in active markets for similar assets and liabilities that are observable for the asset or liability; and ● Level 3: Unobservable pricing inputs that are generally less observable from objective sources, such as discounted cash or valuation models. The financial assets and liabilities are classified in the Consolidated Balance Sheets based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. As disclosed in Note 7, the two tranches, of 2023 Series Convertible Notes Payable - Stock Settled Derivative/Warrant Liability required identification and quantification of fair value. Similarly, the tranche of 2024 Series Senior Secured convertible notes – Stock Settled Derivative/Warrant Liability required identification and quantification of fair value. The derivative liabilities described below only relate to (i) the warrants included with the two tranches of the 2023 Series Convertible Notes Payable – Stock Settled debt and (ii) the warrants included with 2024 Series Senior Secured convertible note – Stock Settled debt. The estimated fair values as of the issuance date of these three tranches of notes are presented in Note 7. As of July 31, 2024, the estimated fair values of the Company’s financial liabilities are presented in the following table: SCHEDULE OF FAIR VALUE ON FINANCIAL LIABILITIES July 31, 2024 2023 Series Convertible Notes Payable - Stock Settled - Derivative/Warrant Liability $ 9,086 2023 Series B Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability 117,792 2024 Series Senior Secured convertible notes payable – stock settled – Derivative/Warrant Liability 155,458 Total $ 282,336 The following table presents a roll forward of the fair value of the derivative liabilities associated with the Company’s warrants included with its 2023 Series and 2024 Series Convertible Notes Payable, categorized as Level 3: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON RECURRING BASIS Nine Months Ended Year Ended October 31, 2023 Beginning Balance $ 893,263 $ - Additions 3,159,789 996,598 Subtractions (990,719 ) - Total (gains) or losses (unrealized) (2,779,997 ) (103,335 ) Ending Balance $ 282,336 $ 893,263 During the three and nine months ended July 31, 2024 and 2023, the unrealized gain on the Derivative Warrant Liability associated with the two tranches of 2023 Series Convertible Notes Payable – Stock Settled was $ 330,274 766,385 58,133 58,840 During the three and nine months ended July 31, 2024, the unrealized (gain) or loss on the Derivative Warrant Liability associated with the 2024 Series Senior Secured convertible notes payable – stock settled was $ 272,030 2,013,612 The fair value of the warrants granted in connection with the two tranches of 2023 Series Convertible Notes Payable-Stock Settled during the periods presented was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED July 31, 2024 October 31, 2023 Risk-free interest rate - % 3.60 3.93 % Dividend yield - % 0.00 % Volatility factor - % 161.52 200.29 % Weighted average expected life (years) - 2.5 The fair value of the warrants granted in connection with the 2024 Series Senior Secured convertible notes payable - stock settled during the periods presented was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED July 31, 2024 October 31, 2023 Risk-free interest rate 3.99 4.61 % - % Dividend yield 0.00 % - % Volatility factor 131.93 135.58 % - % Weighted average expected life (years) 2.5 - Estimated Fair Value of Financial Assets and Liabilities Not Measured at Fair Value The Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable, and Convertible Notes Payable. The carrying values of cash, accounts receivable and accounts payable are representative of their fair values due to their short-term maturities. The carrying amount of the Company’s Convertible Notes Payable approximates fair value as they bear interest over the term of the loans.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Jul. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 – PROPERTY AND EQUIPMENT The following is a summary of property and equipment, less accumulated depreciation at the balance sheet dates: SCHEDULE OF PROPERTY AND EQUIPMENT July 31, 2024 October 31, 2023 Leasehold improvements $ 12,840 $ 12,840 Property and equipment 1,046,925 1,046,925 Total cost 1,059,765 1,059,765 Less accumulated depreciation (879,449 ) (739,351 ) Net property and equipment $ 180,316 $ 320,414 Depreciation expense for the three and nine months ended July 31, 2024 and 2023 was $ 48,313 140,098 39,706 117,745

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Jul. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5 – INTANGIBLE ASSETS The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of July 31, 2024: SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL Remaining Cost Accumulated Net Carrying Trademarks and tradenames 12.00 $ 693,330 $ (408,988 ) $ 284,342 Patents, know-how and unpatented technology 12.00 710,060 (377,437 ) 332,623 Customer relationships 0.00 114,536 (114,536 ) - Total 1,517,926 (900,961 ) 616,965 Remaining Useful Life Cost Impairment Net Carrying Value Goodwill Indefinite $ 4,523,040 $ (914,091 ) $ 3,608,949 The table below presents anticipated future amortization expense related to the Company’s intangible assets for each of the succeeding five fiscal years ending October 31; SCHEDULE OF FUTURE AMORTIZATION EXPENSE 2024 (3 months) $ 12,854 2025 51,416 2026 51,416 2027 51,416 2028 51,416 2029 51,416 Total $ 269,934 During the three and nine months ended July 31, 2024 and 2023, the Company recorded amortization expense of $ 16,952 50,848 32,934 98,802

LEASE OBLIGATIONS

LEASE OBLIGATIONS	9 Months Ended
	Jul. 31, 2024
Lease Obligations
LEASE OBLIGATIONS	NOTE 6 – LEASE OBLIGATIONS The Company accounts for its leases in accordance with ASU No. 2016-02, Leases (Topic 842) (“ASC 842”). The Company’s operating lease consists of a lease for office space. The Company’s finance lease activities consist of leases for equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The office lease contains an option to a renewal period of five years In May 2023, the Company executed a new office lease for 2,978 271,396 271,396 32,103 98,444 12,345 38,032 The following table shows the classification and location of the Company’s leases in the Consolidated Balance Sheets: SCHEDULE OF BALANCE SHEET RELATED TO LEASES Leases Balance Sheet Location July 31, 2024 October 31, 2023 Assets Noncurrent: Operating Right-of-use asset – operating lease $ 377,797 $ 476,241 Finance Property and equipment, net 7,963 33,294 Total Lease Assets $ 385,760 $ 509,535 Liabilities Current: Operating Operating lease liabilities $ 122,140 $ 130,150 Finance Finance lease liabilities 21,052 61,832 Noncurrent: Operating Operating lease liabilities 255,657 346,091 Finance Finance lease liabilities 7,704 17,123 Total Lease Liabilities $ 406,553 $ 555,196 The following table shows the classification and location and the Company’s lease costs in the Consolidated Statements of Operations: SCHEDULE OF OPERATIONS RELATED TO LEASES Location 2024 2023 Statements of Operations Nine Months Ended July 31, Location 2024 2023 Operating lease expense General and administrative expense $ 148,556 $ 149,203 Finance lease expense: Interest on lease liability Interest expense 5,994 7,797 Total Lease expense $ 154,550 $ 157,000 Minimum remaining contractual obligations for the Company’s leases (undiscounted) as of July 31, 2024 were as follows: SCHEDULE OF MINIMUM CONTRACTUAL OBLIGATIONS OF LEASES Operating Finance Fiscal year 2024 $ 40,756 $ 12,048 Fiscal year 2025 163,902 12,803 Fiscal year 2026 166,760 5,150 Fiscal year 2027 84,609 - Fiscal year 2028 67,734 - Fiscal year 2029 67,734 - Thereafter 45,151 - Total Lease Payments $ 636,646 $ 30,001 Less Imputed interest (258,849 ) (1,245 ) Total lease liability $ 377,797 $ 28,756 The following table shows the weighted average remaining lease term and the weighted average discount rate for the Company’s leases as of the dates indicated: SCHEDULE OF OTHER INFORMATION RELATED TO LEASES July 31, 2024 October 31, 2023 Operating Finance Operating Finance Weighted-average remaining lease term (in years) 4.1 1.16 4.9 1.41 Weighted-average discount rate (1) 10.00 % 7.02 % 10.00 % 7.49 % (1) The discount rate used for the operating lease is based on the Company’s incremental borrowing rate at lease commencement and may be adjusted if modification to lease terms or lease reassessments occur. The discount rate used for finance leases is based on the rates implicit in the leases. The following table includes other quantitative information for the Company’s leases for the periods indicated: SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES 2024 2023 Nine Months Ended July 31, 2024 2023 Cash paid for amounts included in measurement of lease liabilities Cash payments for operating leases $ 134,923 $ 111,100 Cash payments for finance leases $ 50,199 $ 46,775

DEBT

DEBT	9 Months Ended
	Jul. 31, 2024
Debt Disclosure [Abstract]
DEBT	NOTE 7 – DEBT The table below presents outstanding debt instruments as of July 31, 2024 and October 31, 2023: SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS July 31, 2024 October 31, 2023 Short Term 2021 Series convertible notes – related party $ 480,000 $ 480,000 2024 Series Senior Secured convertible notes 4,718,750 - Premium 2024 Series Senior Secured convertible notes 146,033 - Total Short-Term Debt 5,344,783 480,000 Long Term Unsecured 6% note payable – related party $ 767,288 $ 767,288 Unsecured 4% note payable – related party 1,221,958 1,221,958 2022 Series convertible notes 200,000 200,000 2023 Series convertible notes – stock settled 405,000 405,000 Discount 2023 Series convertible notes (55,153 ) (64,285 ) 2023 Series B convertible notes – stock settled 1,312,600 1,312,600 Discount 2023 Series B convertible notes (830,396 ) (891,582 ) Total Long-Term Debt 3,021,297 2,950,979 Total Debt $ 8,366,080 $ 3,430,979 The table below presents the future maturities of outstanding debt obligations as of July 31, 2024: SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS Fiscal year 2024 $ 5,198,750 Fiscal year 2025 - Fiscal year 2026 1,989,246 Fiscal year 2027 200,000 Fiscal year 2028 1,717,600 Total $ 9,105,596 Unsecured 6% Note Payable - Related Party Interest expense on this note was $ 11,604 34,560 11,604 34,433 172,672 138,112 Unsecured 4% Note Payable - Related Party Interest expense on this note was $ 12,320 36,692 12,320 36,558 183,327 146,635 2021 Series Convertible Note - Related Party The principal balance outstanding on the 2021 Series Convertible note amounted to $ 480,000 480,000 July 31, 2024 6,049 18,196 6,050 17,951 72,000 53,804 On August 2, 2024, we received a notice of default with respect to this note. We are in negotiations with the holder of the note to extend the maturity date of the note, but there is no assurance we will reach an agreement to extend the maturity date of the note. The note is convertible into our common stock at a price of $ 26.00 3.00 15,000 and (iii) we either have an effective registration statement allowing for resale of the common stock free of any restrictions or the shares are eligible for sale without restriction by the holder upon conversion. Subject to such conditions, the note may be subject to mandatory conversion following completion of an offering, however, there can be no assurance the note will become subject to mandatory conversion. Though the default under this note also constitutes an event of default under certain other outstanding notes issued by the Company, such cross-defaults have been waived by the holders. 2022 Series Convertible Notes During June and July, 2022, the Company issued a total of $ 200,000 5 5,000,000 2,521 7,507 2,521 7,480 20,713 13,205 2023 Series Convertible Notes – Stock Settled On January 6, 2023, the Company sold $ 405,000 8 On various dates during March and April 2023, the Company sold $ 787,600 8 On various dates during June and July 2023, the Company sold $ 525,000 8 The sale and purchase were made through a Convertible Note and Warrant Purchase Agreement (“Purchase Agreement”) entered into with each investor. The Company followed the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 480 “Distinguishing Liabilities from Equity” to account for the stock settled debt and ASC 815 “Derivatives and Hedging” to account for the derivative related to the notes and also to determine the number of warrants to be issued at the time of the issuance of the January 2023 Notes, March 2023 Notes, or the June 2023 Notes. The Company contemplated ASC 480-10-30-7 related to the valuation of the embedded conversion feature contained in the January 2023 Notes, March 2023 Notes, and June 2023 Notes. The Company deemed that the most likely scenario to be utilized for valuing the conversion feature was a qualified financing. Therefore, the Company deemed that the January 2023 Notes, March 2023 Notes, and June 2023 were issued at a premium related to the definition of Discounted Qualified Financing Price contained in the Purchase Agreement. The premium recognized at the inception of January 2023 Notes was $ 135,000 262,533 175,000 The Company assessed the January 2023 Warrants, March 2023 Warrants, and June 2023 first under ASC 480. Based on the attributes of the January 2023 Warrants, March 2023 Warrants, and June 2023 Warrants, the Company determined that each are outside of the scope of ASC 480 and proceeded to assess each under ASC 815 to determine if any are considered indexed to the Company’s own common stock. Because the inputs which affect the number of shares to be issued upon exercise of the January 2023 Warrants, March 2023 Warrants, and June 2023 Warrants are not the inputs per 815-40-15-7E, none are deemed to be indexed to the Company’s own stock and have been recorded as liabilities under ASC 815 (Note 3) at the fair market value. At issuance, the Company recorded a warrant liability related to the January 2023 Warrants of $ 73,213 135,000 73,213 208,213 568,574 262,533 568,574 831,108 354,810 175,000 354,180 529,810 The combination of the $ 135,000 208,213 73,213 13.0 13.0 13.0 13.0 3,164 9,132 23,652 54,883 2,784 6,052 5,871 6,057 The combination of the $ 262,533 831,108 568,574 44.6 44.6 44.6 44.6 13,861 37,305 (183,983) (426,923) 9,073 12,083 45,667 46,187 The combination of the $ 175,000 529,810 354,810 39.5 39.5 8,778 23,882 122,639 284,579 3,007 3,007 6,596 6,596 During the three and nine months ended July 31, 2024 and 2023, the Company recorded $ 8,167 24,322 8,167 18,074 15,881 47,299 15,880 21,432 10,586 31,529 4,964 4,964 As of July 31, 2024 and October 31, 2023, the Company had accrued $ 50,562 26,240 84,613 37,314 47,079 15,551 2024 Series Senior Secured Convertible Notes – Stock Settled On November 16, 2023 and January 10, 2024, the Company entered into securities purchase agreements (the “January Purchase Agreements”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) senior secured convertible notes (the “January Series 2024 Notes”) in the principal amount of $ 2,500,000 1,250,000 2,000,000 1,000,000 20 On April 11, 2024, the Company entered into a securities purchase agreement (the “April Purchase Agreement”) with an accredited investor, pursuant to which the Company issued and sold to the investor, in a private placement, (i) senior secured convertible notes (the “April Series 2024 Notes”) in the principal amount of $ 218,750 175,000 20 On May 13, 2024, the Company entered into securities purchase agreements (the “May Purchase Agreement”) with accredited investors, pursuant to which the Company issued and sold to the investors, in a private placement, (i) senior secured convertible notes (the “May Series 2024 Notes”) in the principal amount of $ 375,000 300,000 20 On June 21, 2024, the Company entered into a letter agreement (the “Target Extension Agreement”) with Target Capital 16 LLC (“Target”). Pursuant to the Target Extension Agreement, the maturity date of the January Series 2024 Notes of the Company held by Target, in the aggregate original principal amount of $ 3,750,000 On July 16, 2024, the Company entered into a second letter agreement (the “Target Consolidation Agreement”) with Target. Pursuant to the Target Consolidation Agreement, in consideration of an additional $ 300,000 3,300,000 825,000 4,125,000 The January Series 2024 Notes, April Series 2024 Notes, May Series 2024 Notes, and July Series 2024 Notes are collectively the “Series 2024 Notes.” The January Series 2024 Warrants, April Series 2024 Warrants, and May Series 2024 Warrants are collectively the “Series 2024 Warrants.” No Series 2024 Warrants were issued with the July Series 2024 Notes. Interest on the Series 2024 Notes will accrue commencing on the earlier of the maturity date or upon an event of default, at the annual rate of 20%, due the first day of each calendar month following such date. The January Series 2024 Notes will mature at the earlier of (i) six months from the issuance date (the “Original Maturity Date”) and (ii) the occurrence of a Liquidity Event (as defined in the January Series 2024 Notes), provided that the Company may extend the maturity date for an additional three months (the “January Extension Period”). The April Series 2024 Notes will mature at the earlier of (i) May 16, 2024 and (ii) the occurrence of a Liquidity Event (as defined in the April Series 2024 Notes), provided that the Company may extend the maturity date for an additional three months (the “April Extension Period”). The May Series 2024 Notes will mature at the earlier of (i) May 16, 2024 and (ii) the occurrence of a Liquidity Event (as defined in the May Series 2024 Notes), provided that the Company may extend the maturity date for an additional three months (the “May Extension Period”). The July Series 2024 Notes will mature on October 16, 2024 (the “Original Final Maturity Date”), provided that, if the Company (A) will have been diligently pursuing the consummation of a Liquidity Event (as defined in the Notes) through such date (as evidenced by the filing of a registration statement under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended) and (y) will have delivered an extension notice, then the Original Final Maturity Date will be extended to November 16, 2024 (the “Extended Final Maturity Date”), and (B) will have consummated a Liquidity Event on or before the Original Final Maturity Date or Extended Final Maturity Date, then the Extended Final Maturity Date will be extended by 180 days from the date of such consummation. The Series 2024 Notes are secured by all of the Company’s assets pursuant to a security agreement between the Company and the investors. The Series 2024 Notes will be convertible, at the option of the investors, into common stock commencing on the maturity date, at a conversion price equal to the product of (x) the Liquidity Event Price (as defined in the Series 2024 Notes) and (y) 0.70 (or 0.60 if the Company has extended the maturity date), provided however, that if no Liquidity Event has occurred by the maturity date then the conversion price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. In addition, the Company will have the right to effect conversion of the Series 2024 Notes if, at the time (a) a Liquidity Event has occurred and (b) the underlying shares are registered for resale. The Series 2024 Warrants will be exercisable into the number the shares of common stock obtained by dividing 100% of the original principal amount of the Series 2024 Notes by (ii) the Liquidity Event Price (as defined in the Series 2024 Notes); provided, however, that if no Liquidity Event has occurred by the maturity date, then such percentage will be 150%. The Series 2024 Warrants will be exercisable for a period of five years and have an exercise price equal to the Liquidity Event Price provided however, that if no Liquidity Event has occurred by the maturity date then the exercise price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. The Company followed the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 480 “Distinguishing Liabilities from Equity” to account for the stock settled debt, ASC 470 “Debt,” and ASC 815 “Derivatives and Hedging” to account for Series 2024 Notes and Series 2024 Warrants. The Company contemplated ASC 480-10-30-7 related to the valuation of the embedded conversion feature contained in the Series 2024 Notes and determined that the value delivered to the investor is identical in all scenarios and only the number of shares differ. The number of shares are issued at a premium as there is a discount applicable in the case of a Liquidity Event. In order to determine the conversion price of the Series 2024 Notes, the Company analyzed the guidance in ASC 470 related to multi-step discounts. The Company deemed that the most likely scenario to be utilized for valuing the conversion feature was a conversion following a Liquidity Event at the option of the investor during the Extension Period as this represents the most advantageous scenario from the perspective of the investor with the shortest period in which the investor could recognize a return on its investment. Because the Company filed an amendment to its Form S-1 Registration Statement on February 2, 2024 which contemplates that, following effectiveness, the selling shareholders may offer their shares at a fixed price of $ 15.00 15.00 416,667 2,500,005 24,306 145,840 41,666 249,990 5.00 6.00 5.50 5.50 1,250,000 249,995 The Company assessed the Series 2024 Warrants first under ASC 480. Based on the attributes of the Series 2024 Warrants, the Company determined that each are outside of the scope of ASC 480 and proceeded to assess each under ASC 815 to determine if any are considered indexed to the Company’s own common stock. Because the inputs which affect the number of shares to be issued upon exercise of the Series 2024 Warrants are not the inputs per 815-40-15-7E, none are deemed to be indexed to the Company’s own stock and have been recorded as liabilities under ASC 815 (Note 3) at the fair market value. Because the scenario under which the Series 2024 Notes are analyzed assumes a Liquidity Event, the scenarios under which to analyze the Series 2024 Warrants should also contain a Liquidity Event. As such, the assumed exercise price is $ 15.00 250,000 14,583 25,000 2,732,304 157,733 269,752 2,500,005 750,000 2,732,304 5,232,309 145,840 43,750 157,733 303,573 249,990 75,000 269,752 519,742 The combination of the $ 2,500,005 750,000 5,232,309 3,482,304 659 624 1,382,897 3,482,304 Pursuant to ASC 480, the Company assessed the January Series 2024 Notes and the July Series 2024 Notes comparing the present value of the cash flows of both notes at the January Series 2024 Notes effective interest rate. Because the difference between the present value of the January Series 2024 Notes and July Series 2024 Notes cash flows was greater than 10%, the two sets of notes were deemed to be substantially different and, as such, the extinguishment of January Series 2024 Notes were recorded as a gain in the statement of operations. Immediately prior to the extinguishment, the Company recorded a gain on the fair value of the warrant liability of $ 1,713,320 300,000 75,000 990,719 249,995 740,724 The combination of the $ 145,840 43,750 303,573 201,483 5000 154,785 201,483 100,462 100,459 The combination of the $ 249,990 75,000 519,742 344,752 104,000 344,752 344,752 171,568 171,568 During the three and nine months ended July 31, 2024, no no

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended
	Jul. 31, 2024
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8– STOCKHOLDERS’ EQUITY Preferred Stock The Company has authorized 5,000,000 0.001 250,000 0 0 Activity for the nine months ended July 31, 2024 and 2023 There were no sales or grants of preferred shares during the nine months ended July 31, 2024 or 2023. Common Stock As of July 31, 2024, the Company had authorized 19,230,770 0.001 4,460,535 4,430,535 Activity for the nine months ended July 31, 2024 and 2023 On November 16, 2023, the Company granted 30,000 15.00 450,000 There were no grants of common stock during the nine months ended July 31, 2023. Stock-Based Compensation There were no The table below presents option activity for the nine months ended July 31, 2024: SCHEDULE OF OPTION ACTiVITY Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Life (in years) Aggregate intrinsic value Balance at October 31, 2023 1,112,923 10.84 6.64 16,889,060 Options exercised - - - - Options granted - - - - Options expired - - - - Options forfeited - - - - Balance at July 31, 2024 1,112,923 $ 10.84 5.89 $ 1,560,431 Stock based compensation expense related to options for the three and nine months ended July 31, 2024 and 2023, amounted to $ 383,429 1,156,280 386,616 902,688 900,872 831,333 2,343,385 3,506,561 Warrants During the nine months ended July 31, 2024, the Company issued pre-funded warrants to purchase 1,060,000 0.01 A summary of the Company’s common stock underlying the outstanding warrants as of July 31, 2024, is as follows: SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS Underlying Number of Average Weighted Outstanding at October 31, 2023 444,454 20.56 1.65 Warrants A – Granted during the period - - - Warrants B – Granted during the period - - - Warrants A – Expired during the period (113,846 ) 13.00 - Warrants B – Expired during the period - - - Outstanding at July 31, 2024 330,608 $ 23.29 1.26

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Jul. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES Employment agreements On July 6, 2022, the Company hired Christopher Furman as its new Chief Executive Officer. Mr. Furman will receive an annual base salary of $ 400,000 100 192,307 26.00 38,461 38,461

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Jul. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 – RELATED PARTY TRANSACTIONS Accounts Payable The spouse of the Company’s Chief Science Officer, through an entity she controls, leases office and lab space to the Company. As of July 31, 2024 and October 31, 2023, the Company owes this entity $ 5,645 28,222 5,645 Convertible Notes, Debt Discount and Accrued Interest The principal balance outstanding on the 2021 Series Convertible note, which is owned by a relative of the former CFO, amounted to $ 480,000 480,000 6,049 18,196 6,050 17,951 72,000 53,804 On August 2, 2024, we received a notice of default with respect to this note. We are in negotiations with the holder of the note to extend the maturity date of the note, but there is no assurance we will reach an agreement to extend the maturity date of the note. The note is convertible into our common stock at a price of $ 26.00 3.00 15,000 and (iii) we either have an effective registration statement allowing for resale of the common stock free of any restrictions or the shares are eligible for sale without restriction by the holder upon conversion. Subject to such conditions, the note may be subject to mandatory conversion following completion of an offering, however, there can be no assurance the note will become subject to mandatory conversion. Though the default under this note also constitutes an event of default under certain other outstanding notes issued by the Company, such cross-defaults have been waived by the holders. Consulting Agreement with 5% Stockholder On December 1, 2021, we entered into a consulting agreement with John Evans (the “Consulting Agreement”), a greater than 5% stockholder and our former Chief Financial Officer, pursuant to which Mr. Evans provides advisory services to our Chief Executive and Chief Financial Officers. Under the Consulting Agreement, Mr. Evans is paid $200,000 per year for his services, increasing to $250,000 per year upon the Company receiving a financing of $10 million or more. The Consulting Agreement further provides that all prior options granted to Mr. Evans under his prior agreements with the Company, specifically those that were granted on May 1, 2018, November 30, 2020, October 1, 2021, shall survive and continue to vest according to their original terms. The Consulting Agreement will terminate on December 1, 2025 (the “Agreement Termination Date”). If Mr. Evans is terminated by the Company for any reason prior to the Agreement Termination Date, or there occurs a Change in Control (as defined in the Consulting Agreement), Mr. Evans will be entitled to the continued payment of amounts due under the Consulting Agreement for the remaining term of the Consulting Agreement, as well as continued vesting of all outstanding options granted to Mr. Evans.

NATURE OF ORGANIZATION AND SU_2

NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jul. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended October 31, 2023, as filed with the SEC (“Form 10-K”). Unless otherwise noted in this Interim Report, there have been no material changes to the disclosures contained in the notes to the audited financial statements for the year ended October 31, 2023, contained in the Form 10-K. The Consolidated Balance Sheet as of October 31, 2023, was derived from the audited financial statements included in the Form 10-K. In management’s opinion, the unaudited interim Consolidated Balance Sheet, Statements of Operations, Statements of Changes in Shareholders’ Equity, and Statements of Cash Flows, contained herein, reflect all adjustments, consisting solely of normal recurring items, which are necessary for the fair presentation of the Company’s financial position, results of operations and cash flows on a basis consistent with that of the Company’s prior audited consolidated financial statements. The results of operations for the interim periods may not be indicative of results to be expected for the full fiscal year. Certain prior period amounts were reclassified to conform to the current presentation on the Consolidated Financial Statements. The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the operations of the Company and its wholly owned subsidiaries, Fitore, Inc. (“Fitore”) and InfiniVive MD, LLC (“InfiniVive”).
Cash Equivalents	Cash Equivalents For the purposes of the Statements of Cash Flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage limits. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Concentrations During the nine months ended July 31, 2024 and 2023, 1 3 30 37 25 10 38 10 25,000 4
Deferred Offering Costs	Deferred Offering Costs The Company defers, as Current Assets, the direct incremental costs of raising capital through equity offerings, until such time as the offering is completed or abandoned. At the time of the offering completion, the costs are charged against the capital raised. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated. During the nine months ended July 31, 2024 and 2023 the Company recorded as expense $ 2,656,962 0
Financial Instruments	Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition As of January 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) (“ASC 606”). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on the Company’s consolidated financial statements. For each performance obligation identified in accordance with ASC 606, the Company determines at contract inception whether it satisfies the performance obligation over time (in accordance with paragraphs 606-10-25-27 through 25-29) or satisfies the performance obligation at a point in time (in accordance with paragraph 606-10-25-30). If an entity does not satisfy a performance obligation over time, the performance obligation is satisfied at a point in time. Control is considered transferred over time if any one of the following criteria is met: ● The customer simultaneously receives and consumes the benefits of the asset or service which the entity performs; ● The entity’s performance creates or enhances an asset; or ● The entity’s performance creates or enhances an asset that has no alternative use to the entity and the entity has the right to payment for work completed to date. For certain contracts to which the Company is party, it uses the recognition over time method to recognize revenue. The Company recognizes revenue when performance obligations with the customer are satisfied. Product sales occur once control is transferred upon shipment to the customer at the time of the sale. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods and services. The Company’s revenue is primarily derived from the sources listed below: Sale of research and development product Sales of research and development product include the sale of stem cell medium Sale of therapeutic product: Includes cell culture media to be used in therapeutic treatment. Shipping: Includes amounts charged to customers for shipping products. Consulting Revenue: The Company has agreed to assist another party to develop an FDA-approved biological product. Revenues are recognized when certain contractual milestones are achieved. Fitore product sales online: Includes internet sales, via the Fitore Nutrition website, of dietary supplements called Stemulife, Spectrum+, Easy Sleep and Thought Calmer. InfiniVive product sales: InfiniVive, via call-in orders, sells exosomes and daily cosmetic serum Disaggregation of revenue The following table summarizes the Company’s revenue for the reporting periods, disaggregated by product or service type: SCHEDULE OF DISAGGREGATION OF REVENUE Three Months Three Months Revenues: Research and development products $ 72,913 $ 284,306 AlloRx Stem Cells to Foreign Third-Party Clinics 214,839 217,991 InfiniVive products 29,236 60,160 Fitore products 2,921 14,783 Total $ 319,909 $ 577,240 Total Revenues $ 319,909 $ 577,240 Nine Months Nine Months Revenues: Research and development products $ 322,870 $ 307,324 AlloRx Stem Cells to Foreign Third-Party Clinics 870,712 661,208 Consulting revenue - 25,000 InfiniVive products 110,817 183,148 Fitore products 12,657 52,434 Total $ 1,317,056 $ 1,229,114 Total Revenues $ 1,317,056 $ 1,229,114
Deferred Revenue	Deferred Revenue The Company has recorded deferred revenue in connection with a Joint Operating Agreement (as subsequently amended, the “JOA”) between the Company and European Wellness/BIO PEP USA (“BIO PEP”). Pursuant to this JOA, which expired in accordance with its terms on July 31, 2023 and has not been renewed, the Company was obligated to use its best efforts to identify, develop and deliver various potential active pharmaceutical ingredients and to oversee the development of a recombinant cell line by a third-party service provider. The Company was also engaged to establish a Quality Management System to be utilized by BIO PEP in their pursuit of FDA authorizations. Prior to its expiration, our work under the JOA had been suspended since April 2023 pending discussions regarding amounts believed to be owed to us under that agreement for work already completed. If those discussions are unsuccessful, we may not be able to collect all of the amounts believed to be owed to us or the other amounts originally expected to be received by us under the agreement. The Company records as deferred revenue amounts for which the Company has been paid but for which it has not yet achieved and delivered related milestones or when the level of effort required to complete performance obligations under an arrangement cannot be reasonably estimated under the terms of the related agreement. Deferred revenue is classified as current or long-term based on when management estimates the revenue will be recognized. As of July 31, 2024, the Company has net deferred $ 525,387 685,005 159,618 The table below summarizes Deferred Revenues as of July 31, 2024: SUMMARY OF DEFERRED REVENUES October 31, Other Project Net Revenue July 31, Deferred Revenue $ 525,387 $ - $ - $ 525,387 Total $ 525,387 $ - $ - $ 525,387 The table below summarizes Deferred Revenues as of July 31, 2023: October 31, Revenue Recognized Revenue July 31, Deferred Revenue $ 650,000 $ (250,000 ) $ 285,005 $ 685,005 Total $ 650,000 $ (250,000 ) $ 285,005 $ 685,005 As of July 31, 2023, upon the expiration of the European Wellness Agreement, the Company recognized $ 250,000 58,254
Accounts Receivable	Accounts Receivable Accounts receivable consists of amounts due from customers. The Company considers accounts more than 30 days old to be past due. The Company uses the allowance method for recognizing bad debts. When an account is deemed uncollectible, it is written off against the allowance. The Company generally does not require collateral for its accounts receivable. As of July 31, 2024 and October 31, 2023, total accounts receivable amounted to $ 69,067 119,671 975 975 As of July 31, 2024, two customers accounted for 46 14 39 35
Basic Loss Per Share	Basic Loss Per Share The Company complies with accounting and disclosure requirements ASC Topic 260, “Earnings Per Share.” Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic income or loss per share) and potentially dilutive shares of common stock that are not anti-dilutive. For the nine months ended July 31, 2024 and 2023, the following number of potentially dilutive shares have been excluded from diluted net loss since such inclusion would be anti-dilutive: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE July 31, 2024 July 31, 2023 Stock options outstanding 1,112,923 1,122,154 Shares to be issued in connection with exercise of warrants 330,608 448,677 2021 Series Convertible Notes Payable - Related Party – common shares 18,462 18,462 2022 Series Convertible Notes Payable - common shares 7,692 7,692 2023 Series Convertible Notes Payable – Stock Settled 30,371 12,854 2023 Series Convertible Notes Payable – Stock Settled – warrants issuable 3,076 3,076 2023 Series B Convertible Notes Payable – Stock Settled 96,286 40,683 2023 Series B Convertible Notes Payable - Stock Settled - warrants issuable 39,881 39,881 2024 Series Senior Secured convertible notes payable – stock settled 398,768 - 2024 Series Senior Secured convertible notes payable – stock settled – warrants issuable- 289,583 - 2024 Pre-funded Warrants 1,060,000 - Total 3,387,650 1,693,479 Anti-dilutive shares 3,387,650 1,693,479
Inventory	Inventory Inventories, consisting of raw materials and finished goods, are stated at the lower of cost (using the specific identification method) or market. Inventories consisted of the following at the balance sheet dates: SCHEDULE OF INVENTORIES July 31, 2024 October 31, 2023 Raw materials $ 21,182 $ 18,856 Finished goods 193,386 151,896 Total inventory $ 214,568 $ 170,752 The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. During the nine months ended July 31, 2024 and 2023, the Company did not record any impairment expense.
Patents	Patents Costs related to filing and pursuing patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) are capitalized as incurred and will not be amortized until a patent is granted at which time they will be amortized. Capitalized patent costs recorded as of July 31, 2024 and October 31, 2023 were $ 82,959 82,325
Recent Accounting Standards	Recent Accounting Standards On August 5, 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, “Debt – Debt With Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40),” which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in GAAP. This ASU is effective for fiscal years beginning after December 31, 2023. The Company is evaluating the impact the adoption will have on the financial statements.

NATURE OF ORGANIZATION AND SU_3

NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Jul. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF DISAGGREGATION OF REVENUE	The following table summarizes the Company’s revenue for the reporting periods, disaggregated by product or service type: SCHEDULE OF DISAGGREGATION OF REVENUE Three Months Three Months Revenues: Research and development products $ 72,913 $ 284,306 AlloRx Stem Cells to Foreign Third-Party Clinics 214,839 217,991 InfiniVive products 29,236 60,160 Fitore products 2,921 14,783 Total $ 319,909 $ 577,240 Total Revenues $ 319,909 $ 577,240 Nine Months Nine Months Revenues: Research and development products $ 322,870 $ 307,324 AlloRx Stem Cells to Foreign Third-Party Clinics 870,712 661,208 Consulting revenue - 25,000 InfiniVive products 110,817 183,148 Fitore products 12,657 52,434 Total $ 1,317,056 $ 1,229,114 Total Revenues $ 1,317,056 $ 1,229,114
SUMMARY OF DEFERRED REVENUES	The table below summarizes Deferred Revenues as of July 31, 2024: SUMMARY OF DEFERRED REVENUES October 31, Other Project Net Revenue July 31, Deferred Revenue $ 525,387 $ - $ - $ 525,387 Total $ 525,387 $ - $ - $ 525,387 The table below summarizes Deferred Revenues as of July 31, 2023: October 31, Revenue Recognized Revenue July 31, Deferred Revenue $ 650,000 $ (250,000 ) $ 285,005 $ 685,005 Total $ 650,000 $ (250,000 ) $ 285,005 $ 685,005
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE July 31, 2024 July 31, 2023 Stock options outstanding 1,112,923 1,122,154 Shares to be issued in connection with exercise of warrants 330,608 448,677 2021 Series Convertible Notes Payable - Related Party – common shares 18,462 18,462 2022 Series Convertible Notes Payable - common shares 7,692 7,692 2023 Series Convertible Notes Payable – Stock Settled 30,371 12,854 2023 Series Convertible Notes Payable – Stock Settled – warrants issuable 3,076 3,076 2023 Series B Convertible Notes Payable – Stock Settled 96,286 40,683 2023 Series B Convertible Notes Payable - Stock Settled - warrants issuable 39,881 39,881 2024 Series Senior Secured convertible notes payable – stock settled 398,768 - 2024 Series Senior Secured convertible notes payable – stock settled – warrants issuable- 289,583 - 2024 Pre-funded Warrants 1,060,000 - Total 3,387,650 1,693,479 Anti-dilutive shares 3,387,650 1,693,479
SCHEDULE OF INVENTORIES	Inventories, consisting of raw materials and finished goods, are stated at the lower of cost (using the specific identification method) or market. Inventories consisted of the following at the balance sheet dates: SCHEDULE OF INVENTORIES July 31, 2024 October 31, 2023 Raw materials $ 21,182 $ 18,856 Finished goods 193,386 151,896 Total inventory $ 214,568 $ 170,752

FAIR VALUE MEASUREMENT (Tables)

FAIR VALUE MEASUREMENT (Tables)	9 Months Ended
	Jul. 31, 2024
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
SCHEDULE OF FAIR VALUE ON FINANCIAL LIABILITIES	As of July 31, 2024, the estimated fair values of the Company’s financial liabilities are presented in the following table: SCHEDULE OF FAIR VALUE ON FINANCIAL LIABILITIES July 31, 2024 2023 Series Convertible Notes Payable - Stock Settled - Derivative/Warrant Liability $ 9,086 2023 Series B Convertible Notes Payable – Stock Settled – Derivative/Warrant Liability 117,792 2024 Series Senior Secured convertible notes payable – stock settled – Derivative/Warrant Liability 155,458 Total $ 282,336
SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON RECURRING BASIS	The following table presents a roll forward of the fair value of the derivative liabilities associated with the Company’s warrants included with its 2023 Series and 2024 Series Convertible Notes Payable, categorized as Level 3: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON RECURRING BASIS Nine Months Ended Year Ended October 31, 2023 Beginning Balance $ 893,263 $ - Additions 3,159,789 996,598 Subtractions (990,719 ) - Total (gains) or losses (unrealized) (2,779,997 ) (103,335 ) Ending Balance $ 282,336 $ 893,263
SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED	The fair value of the warrants granted in connection with the two tranches of 2023 Series Convertible Notes Payable-Stock Settled during the periods presented was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED July 31, 2024 October 31, 2023 Risk-free interest rate - % 3.60 3.93 % Dividend yield - % 0.00 % Volatility factor - % 161.52 200.29 % Weighted average expected life (years) - 2.5
2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED	The fair value of the warrants granted in connection with the 2024 Series Senior Secured convertible notes payable - stock settled during the periods presented was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED July 31, 2024 October 31, 2023 Risk-free interest rate 3.99 4.61 % - % Dividend yield 0.00 % - % Volatility factor 131.93 135.58 % - % Weighted average expected life (years) 2.5 -

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Jul. 31, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	The following is a summary of property and equipment, less accumulated depreciation at the balance sheet dates: SCHEDULE OF PROPERTY AND EQUIPMENT July 31, 2024 October 31, 2023 Leasehold improvements $ 12,840 $ 12,840 Property and equipment 1,046,925 1,046,925 Total cost 1,059,765 1,059,765 Less accumulated depreciation (879,449 ) (739,351 ) Net property and equipment $ 180,316 $ 320,414

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Jul. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL	The following table sets forth the carrying amounts of intangible assets and goodwill including accumulated amortization as of July 31, 2024: SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL Remaining Cost Accumulated Net Carrying Trademarks and tradenames 12.00 $ 693,330 $ (408,988 ) $ 284,342 Patents, know-how and unpatented technology 12.00 710,060 (377,437 ) 332,623 Customer relationships 0.00 114,536 (114,536 ) - Total 1,517,926 (900,961 ) 616,965 Remaining Useful Life Cost Impairment Net Carrying Value Goodwill Indefinite $ 4,523,040 $ (914,091 ) $ 3,608,949
SCHEDULE OF FUTURE AMORTIZATION EXPENSE	The table below presents anticipated future amortization expense related to the Company’s intangible assets for each of the succeeding five fiscal years ending October 31; SCHEDULE OF FUTURE AMORTIZATION EXPENSE 2024 (3 months) $ 12,854 2025 51,416 2026 51,416 2027 51,416 2028 51,416 2029 51,416 Total $ 269,934

LEASE OBLIGATIONS (Tables)

LEASE OBLIGATIONS (Tables)	9 Months Ended
	Jul. 31, 2024
Lease Obligations
SCHEDULE OF BALANCE SHEET RELATED TO LEASES	The following table shows the classification and location of the Company’s leases in the Consolidated Balance Sheets: SCHEDULE OF BALANCE SHEET RELATED TO LEASES Leases Balance Sheet Location July 31, 2024 October 31, 2023 Assets Noncurrent: Operating Right-of-use asset – operating lease $ 377,797 $ 476,241 Finance Property and equipment, net 7,963 33,294 Total Lease Assets $ 385,760 $ 509,535 Liabilities Current: Operating Operating lease liabilities $ 122,140 $ 130,150 Finance Finance lease liabilities 21,052 61,832 Noncurrent: Operating Operating lease liabilities 255,657 346,091 Finance Finance lease liabilities 7,704 17,123 Total Lease Liabilities $ 406,553 $ 555,196
SCHEDULE OF OPERATIONS RELATED TO LEASES	The following table shows the classification and location and the Company’s lease costs in the Consolidated Statements of Operations: SCHEDULE OF OPERATIONS RELATED TO LEASES Location 2024 2023 Statements of Operations Nine Months Ended July 31, Location 2024 2023 Operating lease expense General and administrative expense $ 148,556 $ 149,203 Finance lease expense: Interest on lease liability Interest expense 5,994 7,797 Total Lease expense $ 154,550 $ 157,000
SCHEDULE OF MINIMUM CONTRACTUAL OBLIGATIONS OF LEASES	Minimum remaining contractual obligations for the Company’s leases (undiscounted) as of July 31, 2024 were as follows: SCHEDULE OF MINIMUM CONTRACTUAL OBLIGATIONS OF LEASES Operating Finance Fiscal year 2024 $ 40,756 $ 12,048 Fiscal year 2025 163,902 12,803 Fiscal year 2026 166,760 5,150 Fiscal year 2027 84,609 - Fiscal year 2028 67,734 - Fiscal year 2029 67,734 - Thereafter 45,151 - Total Lease Payments $ 636,646 $ 30,001 Less Imputed interest (258,849 ) (1,245 ) Total lease liability $ 377,797 $ 28,756
SCHEDULE OF OTHER INFORMATION RELATED TO LEASES	The following table shows the weighted average remaining lease term and the weighted average discount rate for the Company’s leases as of the dates indicated: SCHEDULE OF OTHER INFORMATION RELATED TO LEASES July 31, 2024 October 31, 2023 Operating Finance Operating Finance Weighted-average remaining lease term (in years) 4.1 1.16 4.9 1.41 Weighted-average discount rate (1) 10.00 % 7.02 % 10.00 % 7.49 % (1) The discount rate used for the operating lease is based on the Company’s incremental borrowing rate at lease commencement and may be adjusted if modification to lease terms or lease reassessments occur. The discount rate used for finance leases is based on the rates implicit in the leases.
SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES	The following table includes other quantitative information for the Company’s leases for the periods indicated: SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES 2024 2023 Nine Months Ended July 31, 2024 2023 Cash paid for amounts included in measurement of lease liabilities Cash payments for operating leases $ 134,923 $ 111,100 Cash payments for finance leases $ 50,199 $ 46,775

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Jul. 31, 2024
Debt Disclosure [Abstract]
SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS	The table below presents outstanding debt instruments as of July 31, 2024 and October 31, 2023: SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS July 31, 2024 October 31, 2023 Short Term 2021 Series convertible notes – related party $ 480,000 $ 480,000 2024 Series Senior Secured convertible notes 4,718,750 - Premium 2024 Series Senior Secured convertible notes 146,033 - Total Short-Term Debt 5,344,783 480,000 Long Term Unsecured 6% note payable – related party $ 767,288 $ 767,288 Unsecured 4% note payable – related party 1,221,958 1,221,958 2022 Series convertible notes 200,000 200,000 2023 Series convertible notes – stock settled 405,000 405,000 Discount 2023 Series convertible notes (55,153 ) (64,285 ) 2023 Series B convertible notes – stock settled 1,312,600 1,312,600 Discount 2023 Series B convertible notes (830,396 ) (891,582 ) Total Long-Term Debt 3,021,297 2,950,979 Total Debt $ 8,366,080 $ 3,430,979
SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS	The table below presents the future maturities of outstanding debt obligations as of July 31, 2024: SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS Fiscal year 2024 $ 5,198,750 Fiscal year 2025 - Fiscal year 2026 1,989,246 Fiscal year 2027 200,000 Fiscal year 2028 1,717,600 Total $ 9,105,596

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	9 Months Ended
	Jul. 31, 2024
Equity [Abstract]
SCHEDULE OF OPTION ACTiVITY	The table below presents option activity for the nine months ended July 31, 2024: SCHEDULE OF OPTION ACTiVITY Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Life (in years) Aggregate intrinsic value Balance at October 31, 2023 1,112,923 10.84 6.64 16,889,060 Options exercised - - - - Options granted - - - - Options expired - - - - Options forfeited - - - - Balance at July 31, 2024 1,112,923 $ 10.84 5.89 $ 1,560,431
SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS	A summary of the Company’s common stock underlying the outstanding warrants as of July 31, 2024, is as follows: SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS Underlying Number of Average Weighted Outstanding at October 31, 2023 444,454 20.56 1.65 Warrants A – Granted during the period - - - Warrants B – Granted during the period - - - Warrants A – Expired during the period (113,846 ) 13.00 - Warrants B – Expired during the period - - - Outstanding at July 31, 2024 330,608 $ 23.29 1.26

SCHEDULE OF DISAGGREGATION OF R

SCHEDULE OF DISAGGREGATION OF REVENUE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	$ 319,909	$ 577,240	$ 1,317,056	$ 1,229,114
Research and Development Products [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	72,913	284,306	322,870	307,324
AlloRx Stem Cells to Foreign Third Party Clinics [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	214,839	217,991	870,712	661,208
InfiniVive Products [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	29,236	60,160	110,817	183,148
InfiniVive Products [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues	$ 2,921	$ 14,783	12,657	52,434
Consulting Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total Revenues				$ 25,000

SUMMARY OF DEFERRED REVENUES (D

SUMMARY OF DEFERRED REVENUES (Details) - USD ($)	9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Regulatory Liability [Line Items]
Deferred Revenue Beginning	$ 525,387	$ 650,000
Other Project Income Recognized		(250,000)
Revenue Deferred		285,005
Deferred Revenue Ending	525,387	685,005
Deferred Revenue [Member]
Regulatory Liability [Line Items]
Deferred Revenue Beginning	525,387	650,000
Other Project Income Recognized		(250,000)
Revenue Deferred		285,005
Deferred Revenue Ending	$ 525,387	$ 685,005

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED EARNINGS PER SHARE (Details) - shares	9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	3,387,650	1,693,479
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	1,112,923	1,122,154
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	330,608	448,677
2021 Series Convertible Notes Payable - Related Party - Common Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	18,462	18,462
2022 Series Convertible Notes Payable - Common Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	7,692	7,692
2023 Series Convertible Notes Payable – Stock Settlement [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	30,371	12,854
2023 Series Convertible Notes Payable – Stock Settled – Warrants Issuable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	3,076	3,076
2023 Series B Convertible Notes Payable – Stock Settled [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	96,286	40,683
2023 Series B Convertible Notes Payable - Stock Settled - Warrants Issuable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	39,881	39,881
2024 Series Senior Secured Convertible Notes Payable – Stock Settled [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	398,768
2024 Series Senior Secured Convertible Notes Payable – Stock Settled – Warrants Issuable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	289,583
2024 Prefunded Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	1,060,000

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Jul. 31, 2024	Oct. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 21,182	$ 18,856
Finished goods	193,386	151,896
Total inventory	$ 214,568	$ 170,752

NATURE OF ORGANIZATION AND SU_4

NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Oct. 31, 2023
Product Information [Line Items]
Revenue	$ 319,909	$ 577,240	$ 1,317,056	$ 1,229,114
Deferred offering costs	2,656,962	0	2,656,962	0
Deferred revenue current	525,387		525,387		$ 525,387
Composed of deferred revenue	685,005		685,005
Prepaid project cost	159,618		159,618
Accounts receivables, related parties	69,067		69,067		119,671
Allowance for doubtful accounts receivable	975		975		975
Capitalized patent costs	$ 82,959		82,959		$ 82,325
European Wellness Agreement [Member]
Product Information [Line Items]
Deferred revenue current		250,000		250,000
Project related expenses		$ 58,254		58,254
Consulting Revenue [Member]
Product Information [Line Items]
Revenue				$ 25,000
Total revenue percentage			4%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk percentage				38%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | No Customer [Member]
Product Information [Line Items]
Concentration risk percentage			10%	10%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Zamora [Member]
Product Information [Line Items]
Concentration risk percentage			1%	3%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Dr Jack Zamora [Member]
Product Information [Line Items]
Concentration risk percentage			30%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk percentage			37%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage			25%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Three [Member]
Product Information [Line Items]
Concentration risk percentage			10%
Accounts Receivables [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk percentage			46%		39%
Accounts Receivables [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage			14%		35%

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Jul. 31, 2024	Apr. 30, 2024	Jan. 31, 2024	Jul. 31, 2023	Apr. 30, 2023	Jan. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Oct. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 149,080	$ 3,118,919	$ 4,569,186	$ 871,684	$ 1,414,700	$ 1,190,125	$ 7,837,185	$ 3,476,509	$ 5,400,000
Working capital deficit	$ 8,200,000						$ 8,200,000

SCHEDULE OF FAIR VALUE ON FINAN

SCHEDULE OF FAIR VALUE ON FINANCIAL LIABILITIES (Details)	Jul. 31, 2024 USD ($)
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Financial liabilities, fair values	$ 282,336
2023 Series Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Financial liabilities, fair values	9,086
2023 Series B Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Financial liabilities, fair values	117,792
2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Financial liabilities, fair values	$ 155,458

SCHEDULE OF FAIR VALUE DERIVATI

SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON RECURRING BASIS (Details) - Derivative [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($)	9 Months Ended	12 Months Ended
	Jul. 31, 2024	Oct. 31, 2023
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning Balance	$ 893,263
Additions	3,159,789	996,598
Subtractions	(990,719)
Total (gains) or losses (unrealized)	(2,779,997)	(103,335)
Ending Balance	$ 282,336	$ 893,263

SCHEDULE OF FAIR VALUE DERIVA_2

SCHEDULE OF FAIR VALUE DERIVATIVE LIABILITIES ON WARRANTS GRANTED (Details)	9 Months Ended	12 Months Ended
	Jul. 31, 2024	Oct. 31, 2023
Measurement Input, Risk Free Interest Rate [Member] | 2023 Series Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input
Measurement Input, Risk Free Interest Rate [Member] | 2023 Series Convertible Notes Payable [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		3.60
Measurement Input, Risk Free Interest Rate [Member] | 2023 Series Convertible Notes Payable [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		3.93
Measurement Input, Risk Free Interest Rate [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input
Measurement Input, Risk Free Interest Rate [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	3.99
Measurement Input, Risk Free Interest Rate [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.61
Measurement Input, Expected Dividend Payment [Member] | 2023 Series Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		0
Measurement Input, Expected Dividend Payment [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0
Measurement Input, Option Volatility [Member] | 2023 Series Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input
Measurement Input, Option Volatility [Member] | 2023 Series Convertible Notes Payable [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		161.52
Measurement Input, Option Volatility [Member] | 2023 Series Convertible Notes Payable [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input		200.29
Measurement Input, Option Volatility [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input
Measurement Input, Option Volatility [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	131.93
Measurement Input, Option Volatility [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	135.58
Measurement Input, Expected Term [Member] | 2023 Series Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, weighted average expected life		2 years 6 months
Measurement Input, Expected Term [Member] | 2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, weighted average expected life	2 years 6 months

FAIR VALUE MEASUREMENT (Details

FAIR VALUE MEASUREMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Unrealized (gain) loss derivative warrant liability			$ 2,779,997	$ 58,840
2023 Series Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Unrealized (gain) loss derivative warrant liability	$ 330,274	$ 58,133	766,385	$ 58,840
2024 Series Senior Secured Convertible Notes Payable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Unrealized gain on derivatives	$ 272,030		$ 2,013,612

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Jul. 31, 2024	Oct. 31, 2023
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 12,840	$ 12,840
Property and equipment	1,046,925	1,046,925
Total cost	1,059,765	1,059,765
Less accumulated depreciation	(879,449)	(739,351)
Net property and equipment	$ 180,316	$ 320,414

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 48,313	$ 39,706	$ 140,098	$ 117,745

SCHEDULE OF INTANGIBLE ASSETS A

SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)	9 Months Ended
	Jul. 31, 2024	Oct. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Cost	$ 1,517,926
Accumulated Amortization	(900,961)
Net Carrying Value	616,965	$ 667,813
Net Carrying Value	$ 3,608,949	$ 3,608,949
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life	Indefinite
Cost	$ 4,523,040
Impairment	(914,091)
Net Carrying Value	$ 3,608,949
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life	12 years
Cost	$ 693,330
Accumulated Amortization	(408,988)
Net Carrying Value	$ 284,342
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life	12 years
Cost	$ 710,060
Accumulated Amortization	(377,437)
Net Carrying Value	$ 332,623
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life	0 years
Cost	$ 114,536
Accumulated Amortization	(114,536)
Net Carrying Value

SCHEDULE OF FUTURE AMORTIZATION

SCHEDULE OF FUTURE AMORTIZATION EXPENSE (Details)	Jul. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024 (3 months)	$ 12,854
2025	51,416
2026	51,416
2027	51,416
2028	51,416
2029	51,416
Total	$ 269,934

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 16,952	$ 32,934	$ 50,848	$ 98,802

SCHEDULE OF BALANCE SHEET RELAT

SCHEDULE OF BALANCE SHEET RELATED TO LEASES (Details) - USD ($)	Jul. 31, 2024	Oct. 31, 2023	May 31, 2023
Lease Obligations
Operating	$ 377,797	$ 476,241	$ 271,396
Finance	7,963	33,294
Total Lease Assets	385,760	509,535
Operating	122,140	130,150
Finance	21,052	61,832
Operating	255,657	346,091
Finance	7,704	17,123
Total Lease Liabilities	$ 406,553	$ 555,196

SCHEDULE OF OPERATIONS RELATED

SCHEDULE OF OPERATIONS RELATED TO LEASES (Details) - USD ($)	9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Lease Obligations
Operating lease expense	$ 148,556	$ 149,203
Interest on lease liability	5,994	7,797
Total Lease expense	$ 154,550	$ 157,000

SCHEDULE OF MINIMUM CONTRACTUAL

SCHEDULE OF MINIMUM CONTRACTUAL OBLIGATIONS OF LEASES (Details) - USD ($)	Jul. 31, 2024	May 31, 2023
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Operating lease, 2024	$ 40,756
Operating lease, 2025	163,902
Operating lease, 2026	166,760
Operating lease, 2027	84,609
Operating lease, 2028	67,734
Operating lease, 2029	67,734
Operating lease, thereafter	45,151
Operating lease, total lease payments	636,646
Operating lease, less imputed interest	(258,849)
Operating lease, total lease liability	377,797	$ 271,396
Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Finance lease 2024	12,048
Finance lease, 2025	12,803
Finance lease, 2026	5,150
Finance lease, 2027
Operating lease, 2028
Operating lease, 2029
Finance lease, thereafter
Finance lease, total lease payments	30,001
Finance lease, less imputed interest	(1,245)
Finance lease, total lease liability	$ 28,756

SCHEDULE OF OTHER INFORMATION R

SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)		Jul. 31, 2024	Oct. 31, 2023
Lease Obligations
Weighted-average remaining lease term, operating leases		4 years 1 month 6 days	4 years 10 months 24 days
Weighted-average remaining lease term, finance leases		1 year 1 month 28 days	1 year 4 months 28 days
Weighted-average discount rate, operating lease	[1]	10%	10%
Weighted-average discount rate, finance leases	[1]	7.02%	7.49%
[1]The discount rate used for the operating lease is based on the Company’s incremental borrowing rate at lease commencement and may be adjusted if modification to lease terms or lease reassessments occur. The discount rate used for finance leases is based on the rates implicit in the leases.

SCHEDULE OF CASH FLOW INFORMATI

SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($)	9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Lease Obligations
Cash payments for operating leases	$ 134,923	$ 111,100
Cash payments for finance leases	$ 50,199	$ 46,775

LEASE OBLIGATIONS (Details Narr

LEASE OBLIGATIONS (Details Narrative)	3 Months Ended		9 Months Ended
	Jul. 31, 2024 USD ($)	Jul. 31, 2023 USD ($)	Jul. 31, 2024 USD ($)	Jul. 31, 2023 USD ($)	Oct. 31, 2023 USD ($)	May 31, 2023 USD ($) ft²
Lease Obligations
Lessee operating lease renewal term	5 years		5 years
Area of land | ft²						2,978
Operating lease right of use asset	$ 377,797		$ 377,797		$ 476,241	$ 271,396
Operating lease liability	377,797		377,797			$ 271,396
Amortization expense	$ 32,103	$ 12,345	$ 98,444	$ 38,032

SCHEDULE OF OUTSTANDING DEBT IN

SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS (Details) - USD ($)	Jul. 31, 2024	Oct. 31, 2023
Debt Disclosure [Abstract]
2021 Series convertible notes – related party	$ 480,000	$ 480,000
2024 Series Senior Secured convertible notes	4,718,750
Premium 2024 Series Senior Secured convertible notes	146,033
Total Short-Term Debt	5,344,783	480,000
Long Term
Unsecured 6% note payable – related party	767,288	767,288
Unsecured 4% note payable – related party	1,221,958	1,221,958
2022 Series convertible notes	200,000	200,000
2023 Series convertible notes – stock settled	405,000	405,000
Discount 2023 Series convertible notes	(55,153)	(64,285)
2023 Series B convertible notes – stock settled	1,312,600	1,312,600
Discount 2023 Series B convertible notes	(830,396)	(891,582)
Total Long-Term Debt	3,021,297	2,950,979
Total Debt	$ 8,366,080	$ 3,430,979

SCHEDULE OF FUTURE MATURITIES O

SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS (Details)	Jul. 31, 2024 USD ($)
Debt Disclosure [Abstract]
Fiscal year 2024	$ 5,198,750
Fiscal year 2025
Fiscal year 2026	1,989,246
Fiscal year 2027	200,000
Fiscal year 2028	1,717,600
Total	$ 9,105,596

DEBT (Details Narrative)

DEBT (Details Narrative) - USD ($)								1 Months Ended								3 Months Ended		9 Months Ended		11 Months Ended	12 Months Ended
	Aug. 02, 2024	Jul. 16, 2024	May 13, 2024	Apr. 11, 2024	Jan. 10, 2024	Nov. 16, 2023	Jan. 06, 2023	Jul. 31, 2023	Jun. 30, 2023	Apr. 30, 2023	Mar. 31, 2023	Jan. 31, 2023	Jul. 31, 2022	Jul. 30, 2022	Jun. 30, 2022	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Sep. 30, 2024	Oct. 31, 2023	Jul. 01, 2024	Jun. 21, 2024	Apr. 30, 2024
Debt Instrument [Line Items]
Share price																						$ 5.50
Inception of stock settled debt									$ 175,000		$ 262,533	$ 135,000
Warrant liability value																$ 155,458		$ 155,458
Warrant liability																126,878		126,878			893,263
Accretion expense																		$ 4,069,895	$ 21,143
Number of shares, exercised
Minimum [Member]
Debt Instrument [Line Items]
Share price																						5
Maximum [Member]
Debt Instrument [Line Items]
Share price																						6
Target Consolidation Agreement [Member]
Debt Instrument [Line Items]
Additional paid		$ 300,000
Subscription amount		3,300,000
Original issue discount		825,000
Original principal amount		$ 4,125,000
January 2023 Notes [Member]
Debt Instrument [Line Items]
Accrued interest																50,562		$ 50,562			26,240
Beneficial conversion feature																		135,000
Debt discount																208,213		208,213
Debt net discount																$ 73,213		$ 73,213
Effective interest rate								13%								13%	13%	13%	13%
Accretion expense																$ 3,164	$ 2,784	$ 9,132	$ 6,052
Fair value adjustment of warrants																23,652	5,871	54,883	6,057
Interest expense, debt																8,167	$ 8,167	24,322	$ 18,074
March 2023 Notes [Member]
Debt Instrument [Line Items]
Accrued interest																84,613		84,613			37,314
Beneficial conversion feature																		262,533
Debt discount																$ 831,108		$ 831,108
Debt net discount																								$ 568,574
Effective interest rate								44.60%								44.60%	44.60%	44.60%	44.60%
Accretion expense																$ 13,861	$ 9,073	$ 37,305	$ 12,083
Fair value adjustment of warrants																(183,983)	45,667	(426,923)	46,187
Interest expense, debt																15,881	15,880	47,299	21,432
June 2023 Notes [Member]
Debt Instrument [Line Items]
Accrued interest																47,079		47,079			15,551
Beneficial conversion feature																		175,000
Debt discount																529,810		529,810
Debt net discount																$ 354,810		$ 354,810
Effective interest rate																39.50%		39.50%
Accretion expense																$ 8,778	3,007	$ 23,882	3,007
Fair value adjustment of warrants																122,639	6,596	284,579	6,596
Interest expense, debt																10,586	4,964	31,529	4,964
2024 Series Senior Secured Convertible [Member]
Debt Instrument [Line Items]
Accrued interest																$ 0		$ 0			0
Share price																$ 15		$ 15
Purchase price			$ 300,000	$ 175,000	$ 1,000,000	$ 2,000,000
Interest expense, debt																$ 0		$ 0
Principal amount			$ 375,000	$ 218,750	$ 1,250,000	$ 2,500,000																	$ 3,750,000
Discount rate			20%	20%	20%	20%
2024 January Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Beneficial conversion feature																		249,995
Debt discount																5,232,309		5,232,309
Debt net discount																3,482,304		3,482,304
Effective interest rate					624%	659%
Accretion expense																1,382,897		3,482,304
Fair value adjustment of warrants																		1,713,320
Original issuance discount																		750,000
Debt issuance discount																		75,000
Beneficial conversion feature																2,500,005		2,500,005
Additional extinguishment of gross proceeds																		300,000
Extinguishment of original warrant liability																		990,719
Gain on transition																		740,724
2024 April Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Beneficial conversion feature																		145,840
Debt discount																303,573		303,573
Debt net discount																$ 201,483		$ 201,483
Effective interest rate																5,000%		5,000%
Accretion expense																$ 154,785		$ 201,483
Fair value adjustment of warrants																100,462		100,459
Debt issuance discount																		43,750
2024 May Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Beneficial conversion feature																		249,990
Debt discount																519,742		519,742
Debt net discount																$ 344,752		$ 344,752
Effective interest rate																104,000%		104,000%
Accretion expense																$ 344,752		$ 344,752
Fair value adjustment of warrants																171,568		171,568
Debt issuance discount																		$ 75,000
January 2023 Notes and January 2023 Warrants [Member]
Debt Instrument [Line Items]
Beneficial conversion feature												135,000
Warrant liability												73,213
Debt discount												208,213
March 2023 Notes and March 2023 Warrants [Member]
Debt Instrument [Line Items]
Beneficial conversion feature											262,533
Warrant liability											568,574
Debt discount											831,108
June 2023 Warrants [Member]
Debt Instrument [Line Items]
Beneficial conversion feature									175,000
Warrant liability									354,180
Debt discount									529,810
2024 July Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Share price																						$ 5.50
January 2023 Warrants [Member]
Debt Instrument [Line Items]
Warrant liability value												$ 73,213
March 2023 Warrants [Member]
Debt Instrument [Line Items]
Warrant liability											568,574
June 2023 Warrants [Member]
Debt Instrument [Line Items]
Warrant liability									354,810
Series 2024 Warrants [Member] | 2024 Series Senior Secured Convertible [Member]
Debt Instrument [Line Items]
Debt conversion, description																		The Series 2024 Notes will be convertible, at the option of the investors, into common stock commencing on the maturity date, at a conversion price equal to the product of (x) the Liquidity Event Price (as defined in the Series 2024 Notes) and (y) 0.70 (or 0.60 if the Company has extended the maturity date), provided however, that if no Liquidity Event has occurred by the maturity date then the conversion price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis. In addition, the Company will have the right to effect conversion of the Series 2024 Notes if, at the time (a) a Liquidity Event has occurred and (b) the underlying shares are registered for resale.
Warrant exercisable and liquidity event description																		The Series 2024 Warrants will be exercisable into the number the shares of common stock obtained by dividing 100% of the original principal amount of the Series 2024 Notes by (ii) the Liquidity Event Price (as defined in the Series 2024 Notes); provided, however, that if no Liquidity Event has occurred by the maturity date, then such percentage will be 150%. The Series 2024 Warrants will be exercisable for a period of five years and have an exercise price equal to the Liquidity Event Price provided however, that if no Liquidity Event has occurred by the maturity date then the exercise price will be the amount obtained by dividing (i) $95,000,000 by (ii) the number of shares of common stock outstanding on such date calculated on a fully-diluted basis.
Exercise price of warrants																								$ 15
Series 2024 Warrants [Member] | 2024 January Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Beneficial conversion feature																		$ 2,500,005
Warrant liability																2,732,304		2,732,304
Debt discount																5,232,309		$ 5,232,309
Number of shares, exercised																		250,000
Series 2024 Warrants [Member] | 2024 April Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Warrant liability value																157,733		$ 157,733
Beneficial conversion feature																		145,840
Warrant liability																157,733		157,733
Debt discount																303,573		$ 303,573
Number of shares, exercised																		14,583
Debt issuance discount																		$ 43,750
Series 2024 Warrants [Member] | 2024 May Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Warrant liability value																269,752		269,752
Beneficial conversion feature																		249,990
Warrant liability																269,752		269,752
Debt discount																519,742		$ 519,742
Number of shares, exercised																		25,000
Debt issuance discount																		$ 75,000
Common Stock [Member] | 2024 January Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Stock issued upon conversion																		416,667
Stock issued upon conversion, value																		$ 2,500,005
Common Stock [Member] | 2024 April Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Stock issued upon conversion																		24,306
Stock issued upon conversion, value																		$ 145,840
Common Stock [Member] | 2024 May Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Stock issued upon conversion																		41,666
Stock issued upon conversion, value																		$ 249,990
Common Stock [Member] | 2024 July Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Stock issued upon conversion																		1,250,000
Stock issued upon conversion, value																		$ 249,995
Common Stock [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Conversion of common stock price per share	$ 26
Share price	$ 3
Common Stock [Member] | Subsequent Event [Member] | Other Trading [Member]
Debt Instrument [Line Items]
Shares issued	15,000
Unsecured 6% Note Payable Related Party Debt [Member]
Debt Instrument [Line Items]
Interest expense																11,604	11,604	34,560	34,433
Accrued interest																172,672		172,672			138,112
Unsecured 4% Note Payable Related Party Debt [Member]
Debt Instrument [Line Items]
Interest expense																12,320	12,320	36,692	36,558
Accrued interest																183,327		183,327			146,635
2021 Series Convertible Note - Related Party Debt [Member]
Debt Instrument [Line Items]
Interest expense																6,049	6,050	18,196	17,951
Convertible notes payable																480,000		480,000			480,000
Debt instrument, maturity date																				Jul. 31, 2024
Accrued interest																		72,000			53,804
2022 Series Convertible Notes [Member]
Debt Instrument [Line Items]
Interest expense																2,521	$ 2,521	7,507	$ 7,480
Accrued interest																$ 20,713		$ 20,713			$ 13,205
Convertible notes payable													$ 5,000,000		$ 5,000,000
Purchase price													$ 200,000		$ 200,000
Debt instrument, convertible, threshold percentage of stock price trigger														5%	5%
2023 Series Convertible Notes Stock Settled [Member]
Debt Instrument [Line Items]
Purchase price							$ 405,000	$ 525,000	$ 525,000	$ 787,600	$ 787,600
Debt instrument, convertible, threshold percentage of stock price trigger							8%	8%	8%	8%	8%

SCHEDULE OF OPTION ACTiVITY (De

SCHEDULE OF OPTION ACTiVITY (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jul. 31, 2024	Oct. 31, 2023
Equity [Abstract]
Number of Shares, Balance	1,112,923
Weighted Average Exercise Price per Share, Balance	$ 10.84
Weighted Average Remaining Contractual Life (in years)	5 years 10 months 20 days	6 years 7 months 20 days
Aggregate intrinsic value, Balance	$ 16,889,060
Number of Shares, Exercised
Weighted Average Exercise Price per Share, Exercised
Number of Shares, Granted
Weighted Average Exercise Price per Share, Granted
Number of Shares, Expired
Weighted Average Exercise Price per Share, Expired
Number of Shares, Forfeited
Weighted Average Exercise Price per Share, Forfeited
Number of Shares, Balance	1,112,923	1,112,923
Weighted Average Exercise Price per Share, Balance	$ 10.84	$ 10.84
Aggregate intrinsic value, Balance	$ 1,560,431	$ 16,889,060

SCHEDULE OF COMMON STOCK UNDERL

SCHEDULE OF COMMON STOCK UNDERLYING OUTSTANDING WARRANTS (Details) - $ / shares	9 Months Ended	12 Months Ended
	Jul. 31, 2024	Oct. 31, 2023
Class of Warrant or Right [Line Items]
Underlying number of shares beginning	444,454
Average exercise price beginning	$ 20.56
Weighted average life ending	1 year 3 months 3 days	1 year 7 months 24 days
Underlying number of shares ending	330,608	444,454
Average exercise price ending	$ 23.29	$ 20.56
Warrants A [Member]
Class of Warrant or Right [Line Items]
Underlying number of shares granted
Average exercise price, granted
Underlying number of shares expirations	(113,846)
Average exercise price, expired	$ 13
Warrants B [Member]
Class of Warrant or Right [Line Items]
Underlying number of shares granted
Average exercise price, granted
Underlying number of shares expirations
Average exercise price, expired

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)		3 Months Ended			9 Months Ended
	Nov. 16, 2023	Jul. 31, 2024	Jan. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Oct. 31, 2023
Class of Stock [Line Items]
Preferred stock, shares authorized		5,000,000			5,000,000		5,000,000
Preferred stock, par value		$ 0.001			$ 0.001		$ 0.001
Common stock, shares authorized		19,230,770			19,230,770		19,230,770
Common stock, par value		$ 0.001			$ 0.001		$ 0.001
Common stock, shares issued		4,460,535			4,460,535		4,430,535
Common stock, shares outstanding		4,460,535			4,460,535		4,430,535
Number of shares granted					0	0
Stock based compensation expense		$ 383,429		$ 386,616	$ 1,156,280	$ 902,688
Share based compensation options, exercisable		900,872			900,872		831,333
Unrecognized compensation expense		$ 2,343,385			$ 2,343,385		$ 3,506,561
Prefunded Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase common stock		1,060,000			1,060,000
Warrants exercise price per share		$ 0.01			$ 0.01
Common Stock [Member]
Class of Stock [Line Items]
Shares granted			30,000
Common Stock [Member] | Consulting Agreement [Member]
Class of Stock [Line Items]
Shares granted	30,000
Shares granted, price per share	$ 15
Consulting expense					$ 450,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		250,000			250,000		250,000
Preferred stock, shares issued		0			0		0
Preferred stock, shares outstanding		0			0		0

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		9 Months Ended
	Jul. 06, 2022	Jul. 31, 2024
Common stock purchase options exercise price
Christopher Furman [Member] | Employment Agreements [Member]
Annual base salary	$ 400,000
Annual bonus percentage	100%
Common stock purchase options	192,307
Common stock purchase options exercise price	$ 26
Share based compensation, options vested	38,461

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended
	Aug. 02, 2024	Dec. 01, 2021	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Oct. 31, 2023
Debt Instrument [Line Items]
Rent payable			$ 5,645		$ 5,645		$ 28,222
Rent per month					5,645
Consulting Agreement [Member]
Debt Instrument [Line Items]
Consulting agreement description		Mr. Evans is paid $200,000 per year for his services, increasing to $250,000 per year upon the Company receiving a financing of $10 million or more. The Consulting Agreement further provides that all prior options granted to Mr. Evans under his prior agreements with the Company, specifically those that were granted on May 1, 2018, November 30, 2020, October 1, 2021, shall survive and continue to vest according to their original terms.
Subsequent Event [Member]
Debt Instrument [Line Items]
Common stock price per share	$ 26
Conversion of shares	15,000
Subsequent Event [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Common stock price per share	$ 3
2021 Series Unsecured Convertible Notes [Member]
Debt Instrument [Line Items]
Convertible notes payable			480,000		480,000		480,000
Interest expense			6,049	$ 6,050	18,196	$ 17,951
Interest payable current			$ 72,000		$ 72,000		$ 53,804